Oncolytics Biotech is an immuno-oncology company focused on advancing pelareorep, an intravenously delivered immuno-oncolytic virus, toward regulatory approval in metastatic breast cancer and other indications with high unmet needs. Oncolytics’ diverse clinical pipeline is supported by compelling clinical data demonstrating pelareorep’s safety, efficacy, immunotherapeutic mechanism of action, and potential to increase the proportion of patients responding to immune checkpoint inhibitors.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):